Name: ARS Pharmaceuticals, Inc. (SPRY) Financial Statements
Creator: FinSpry

ARS Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

ARS Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	89.15	0.03	1.32	5.51	17.84
Cost of Revenue	20.56	20.27	17.12	20.27	14.07
Gross Profit	68.59	-20.24	-15.80	-14.77	3.77
Operating Expenses
Research & Development	19.58	20.27	18.38	20.27	24.58
Selling, General & Administrative	0.00	47.28	18.46	4.69	4.23
Operating Expenses	71.68	47.28	36.83	4.69	4.23
Operating Income	-3.08	-67.52	-35.52	-19.45	-0.47
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	-0.03
Interest Expense	0.00	0.00	0.00	-0.80	-0.40
Other Income/Expense	11.37	6.01	0.83	0.01	0.00
Income
Income Before Tax	8.29	-54.37	-34.68	-20.24	-1.07
Income Tax Expense	0.29	-0.09	-0.02	0.00	0.00
Net Income	8.00	-54.37	-34.68	-20.24	-1.07
Net Income - Continuous Operations	8.00	-54.37	-34.68	-20.24	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-3.00	-67.45	-35.20	-19.24	-0.46
EBIT	8.29	-67.52	-35.52	-19.45	-0.47
Depreciation & Amortization	0.08	0.07	0.32	0.21	0.01
Earnings Per Share
Basic EPS	-	-1.00	-1.00	-1.00	-
Diluted EPS	-	-1.00	-1.00	-1.00	-
Basic Shares Outstanding	96.94	95.22	39.96	28.87	20.22
Diluted Shares Outstanding	102.39	95.22	39.96	28.87	20.22